ライフサイエンスコーパス: high-dose group

1 medium-dose group), or 25 mg BID carvedilol (high-dose group).

2 (93 in the standard-dose group and 97 in the high-dose group).

3 ] in the low-dose group, and 20 [34%] in the high-dose group).

4 a slight increase in minor infections in the high dose group.

5 jection and neurotoxicity were lowest in the high dose group.

6 had a trend toward better improvement in the high-dose group.

7 agonist adverse effects were observed in the high-dose group.

8 ime, and it may have improved dyspnea in the high-dose group.

9 ) to the low-dose group, and 58 (34%) to the high-dose group.

10 ept for more early steroid withdrawal in the high-dose group.

11 .95% in the low-dose group and 33.62% in the high-dose group.

12 the medium-dose group, and 90% (n=10) in the high-dose group.

13 0.18% in the low-dose group and 52.6% in the high-dose group.

14 low- and mid-dose groups, and lowest in the high-dose group.

15 low-dose group, and 17 (8%) patients in the high-dose group.

16 group and 13 (33%) of 39 participants in the high-dose group.

17 was significantly delayed (P < 0.05) in the high-dose group.

18 ) and greater, but not significantly, in the high-dose group.

19 5% confidence interval: 0.65 to 0.79) in the high-dose group.

20 v-specific CD8 T cells were seen only in the high-dose group.

21 rmediate-dose group, and five of five in the high-dose group.

22 IgG with the highest levels observed in the high-dose group.

23 ups, and 0.4 in the phenethyl isothiocyanate high-dose group.

24 the medium-dose group, and 59 percent in the high-dose group.

25 nd exercise capacity occurred in medium- and high-dose groups.

26 ow-dose and 0.54 (95% CI: 0.46-0.63) for the high-dose groups.

27 the medium-dose group (11.25x10(11)) or the high-dose group (19.63x10(11)) (P=0.002 for low vs. medi

28 of host inflammatory and hemostatic systems (high-dose group, 2.0 microg/kg; n = 5) to renal failure

29 For the high dose group, 20 of 64 base substitutions occurred at

30 180 to 25.5 mug/mL (95% CI 20.6-31.5) in the high-dose group, 22.1 mug/mL (19.3-28.6) in the low-dose

31 was significantly lower in the short-course, high-dose group (24%) compared with the standard-course

32 (2) (mean+/-SE) increased at 6 months in the high-dose group (24.0+/-4.2 mm Hg, 95% CI 15.5 to 32.4 m

33 nt, reported in 25 (62%) participants in the high-dose group, 25 (60%) participants in the low-dose g

34 ive response of splenocytes from rats in the high dose group (250 microg) to alpha3(IV)NC1 in vitro.

35 events in 30 (75%) of 40 participants in the high-dose group, 33 (79%) of 42 participants in the low-

36 the majority of bradycardia occurring in the high-dose group (37.5%).

37 om/s, p < 0.05), was higher in the CHF/ET(A) High Dose group (39+/-1 microm/s, p < 0.05), and was sim

38 ay 28 at 51 mug/mL (95% CI 41.1-63.3) in the high-dose group, 44.9 mug/mL (25.8-56.3) in the low-dose

39 In the high-dose groups (560 and 980 mg dose groups), a respons

40 to treatment was higher in the short-course, high-dose group (82% vs 74%; P =.02).

41 zation (loss of less than 15 letters) in the high-dose group (96.3%) compared with low-dose (83.3%) a

42 In the high-dose group, a consistent increase in the factor IX

43 Reductions in insulin AUC were larger in the high-dose group (adjusted mean difference, -3.56 [95% CI

44 tal admissions was 0.0937 (SD 0.3644) in the high-dose group and 0.1017 (0.3708) in the standard-dose

45 r child was 1.05 (95% CI, 0.91-1.19) for the high-dose group and 1.03 (95% CI, 0.90-1.16) for the sta

46 Nineteen (33%) of 57 patients in the high-dose group and 11 (20%) of 54 patients in the moder

47 er injection in 12 (30%) participants in the high-dose group and 11 (26%) participants in the low-dos

48 s of an event within 2 years of 18.0% in the high-dose group and 18.6% in the low-dose group.

49 48.7 ng/mL (95% CI, 46.9-50.5 ng/mL) in the high-dose group and 36.8 ng/mL (95% CI, 35.4-38.2 ng/mL)

50 dropped 4.8+/-10.3 (mean+/-SD) units in the high-dose group and 6.9+/-8.4 units in the low-dose grou

51 ction was 79.3% (SE 4.0) for patients in the high-dose group and 75.5% (4.2) for the low-dose group.

52 mpare the incidence of MRD positivity of the high-dose group and the low-dose group at day 22 of indu

53 sed by 120%, was normalized in the CHF/ET(A) High Dose group, and fell by 43% from CHF values in the

54 patients in the medium-dose group, 3 in the high-dose group, and 1 in the placebo group discontinued

55 dose group, 17 of 52 patients (32.7%) in the high-dose group, and 9 of 58 patients (15.5%) in the pla

56 e than 30% in 2008 and by 24% in 2009 in the high-dose group as compared with that in the placebo gro

57 ssignment: the relative risk of death in the high-dose group as compared with the standard-dose group

58 7 and week 10 in 4 of the 6 patients in the high-dose group but resolved over a median of 5 days (ra

59 ficiency was observed more frequently in the high-dose group, but the 2 groups were similar in the nu

60 oup and a nonsignificantly lower risk in the high-dose group by 2% for stroke, 7% for CHD events, and

61 roup B), or 7.2 mg of DNA administered i.m. (high-dose group C) each time.

62 d necrosis were significantly reduced in the high dose group compared with the control group.

63 nses was elevated in PBMCs isolated from the high dose group compared with the low dose group.

64 , urinary FB1 was significantly decreased in high-dose group compared to that of placebo group (p = 0

65 There was a 0.8 mean letter gain in the high-dose group compared with a 9.7 mean letter loss in

66 fforded a significant stronger effect in the high-dose group compared with low-dose propofol.

67 evels of tissue-specific ACE activity in the high-dose group compared with the low-dose group at the

68 in outcome for either aptiganel (low-dose or high-dose) group compared with the placebo group at 90 d

69 Plasma from animals in the high-dose group completely inhibited platelet aggregatio

70 tene significantly increased in the mid- and high dose groups during the trial.

71 ct that was significantly more common in the high-dose group during treatment.

72 In contrast, the high-dose group experienced a statistically significant

73 n rates after vaccination were higher in the high-dose group for the H1N1 (96% vs. 87%; treatment dif

74 red with the low-dose group, patients in the high-dose group had a nonsignificant 8% lower risk of de

75 The high-dose group had significantly fewer illicit opioid-p

76 The high-dose group had significantly greater decreases in i

77 The high-dose group had significantly lower mean white blood

78 eat analysis through week 30 patients in the high-dose group had significantly lower rates of opioid-

79 The high-dose group had significantly lower self-reported he

80 There were more clinic attendances by the high-dose group in the first 6 months of life (p=0.018).

81 ognized by postvaccination sera from the two high-dose groups, including large segments spanning the

82 ; 12 months: P=0.054), with the low-dose and high-dose groups individually showing trends toward impr

83 segments and in 1313 of 1360 segments in the high-dose group (kappa = 0.73), in 1321 of 1354 and in 1

84 better revealed that 100% of patients in the high-dose group lost <15 letters compared with 55.6% in

85 between dose groups in treatment retention (high-dose group mean retention, 159 days; moderate-dose

86 tients' global assessment of symptoms in the high-dose group (mean AUC, 4430+/-1401 vs. 4171+/-1436;

87 were randomly allocated into 5 groups: BSJYD high dose group, middle dose group, low dose group, capt

88 activity and serum aldosterone levels in the high-dose group, no statistically significant difference

89 ) in the low-dose group, and two (3%) in the high-dose group; only one (an acute allergic skin reacti

90 (low dose group), 500 U/kg of human AT-III (high dose group), or normal saline (control group) on da

91 f rVSVDeltaG-ZEBOV-GP (1 x 108 pfu, n = 264; high-dose group), or placebo (n = 133).

92 se group, and 17 (8%) of 211 patients in the high-dose group, or diarrhoea, reported by seven (3%) pa

93 D]) to 12 weeks (391.1 +/- 153.0 min) in the high dose group (p < 0.01).

94 eeks for lag phase for the placebo, mid- and high dose groups (p = 0.004 for trend).

95 P < 0.001) and a 37% higher mortality in the high-dose group (P < 0.001).

96 ared with 26.9% (95% CI, 18.3%-37.8%) in the high-dose group (P = .03).

97 placebo, 22% in the low-dose, and 17% in the high-dose group (p = .26 for placebo vs. high dose).

98 statin group (p trend <0.001) but not in the high-dose group (p = 0.03 for test for interaction of BM

99 versus placebo), 18 patients (34.6%) in the high-dose group (P = 0.103 versus placebo), and 29 patie

100 low-dose group and 0.10 mg/dl per yr in the high-dose group (P: = 0.51).

101 ESRD: 10 in the low-dose group and 8 in the high-dose group (P: = 0.56).

102 asone group compared with 87% (82-92) in the high-dose group (p=0.0002).

103 21% in the low-dose group versus 33% in the high-dose group (P=0.007) and 23% in the thyrotropin alf

104 he mean (+/-SE) scores were 2.8+/-0.1 in the high-dose group (P=0.008) and 2.8+/-0.1 in the low-dose

105 , the mean scores were 2.7+/-0.1 in both the high-dose group (P=0.048) and the low-dose group (P=0.14

106 ompared to placebo, which was significant in high-dose groups (P = 0.008 and P < 0.001, respectively)

107 ts in the low-dose, and four patients in the high-dose groups (p = 0.12); 30-day myocardial infarctio

108 s. three in the medium-dose and three in the high-dose group; P<0.001 for low vs. medium and low vs.

109 However, a high-dose group receiving 112.5mg/kg DE showed a conside

110 n 90% reduction in illicit opioid use by the high-dose group relative to pretreatment levels.

111 w-dose group, the medium-dose group, and the high-dose group, respectively (differences were not sign

112 d 2 h (7.70 +/- 6.8 mumol/L) in the low- and high-dose groups, respectively (P < 0.05).

113 A at baseline (94% and 97% for the low- and high-dose groups, respectively) but for only 22% and 14%

114 nd 10 patients in the placebo, low-dose, and high-dose groups, respectively, completed at least 4 wee

115 and 7 patients in the placebo, low-dose, and high-dose groups, respectively, were enrolled in the ope

116 mol (P < 0.001) vs. saline for both low- and high-dose groups, respectively.

117 tion in serum T4, in the dams of the low and high-dose groups, respectively.

118 y 22% and 14% at peak times for the low- and high-dose groups, respectively.

119 .6, and 2.1 hours for the low-, medium-, and high-dose groups, respectively; P=0.028).

120 1.3; P=0.5) and 23.0 percent of those in the high-dose group (risk ratio, 1.2; 95 percent confidence

121 tibility was also lower in the short-course, high-dose group (RR, 0.77; 95% CI, 0.58-1.03; P =.08).

122 .04; 95% CI, 1.50 to 2.76; P < 0.0001 in the high-dose group; RR relative to the middle quintiles).

123 ggested a 6.4% increase (P=0.069), while the high-dose group showed a 7.9% increase (P=0.040) over pl

124 e fovea (P < or = 039), with response in the high-dose group significantly different from that in the

125 ulmonary cavities developed in both low- and high-dose groups, some beginning as early as 6 weeks.

126 More patients in the high-dose group than in the low-dose group were hospital

127 homocysteine was 2 micromol/L greater in the high-dose group than in the low-dose group, but there wa

128 se with > or = 2 functions) were seen in the high-dose group than in the other groups.

129 beats/min) was more frequently noted in the high-dose group than in the standard-dose group (p < .05

130 he equilibrated Kt/V was 1.16+/-0.08; in the high-dose group, the values were 75.2+/-2.5 percent, 1.7

131 to P=.042) in the low-dose group than in the high-dose group; this finding was consistent with recept

132 was diarrhea, which caused 1 patient in the high-dose group to withdraw from the trial.

133 th 31 nmol of 99mTc-labeled Cy7 tilmanocept (high-dose group) to saturate the receptor sites within t

134 group = valganciclovir 450 mg/day [n = 130]; high-dose group = valganciclovir 900 mg/day [n = s7]) we

135 The high-dose group versus placebo met the prespecified crit

136 95 months (95% CI, 3.02-5.95 months) for the high-dose group vs 3.29 months (95% CI, 2.66-4.14 months

137 k of HIV progression or death was 72% in the high-dose group vs 72% in the standard-dose group (risk

138 2000 IU/d of vitamin D oral supplementation (high-dose group) vs 354 participants who were randomized

139 The median daily dose in the high-dose group was 9 MIU (interquartile range [IQR], 9-

140 arked incorporation of deuterated Met in the high-dose group was accompanied with a striking increase

141 ity rate in the lowest eKt/V quintile of the high-dose group was higher than in the full standard-dos

142 us 11.0+/-1.2, P=0.035); measurements in the high-dose group were also lower, but not significantly.

143 ical characteristics between the control and high-dose group were similar for age (95% confidence int

144 41 patients in low-dose and 4330 patients in high-dose groups) were included.